B. Riley Cuts Earnings Estimates for PDS Biotechnology

PDS Biotechnology Co. (NASDAQ:PDSB) – B. Riley dropped their FY2024 earnings estimates for shares of PDS Biotechnology in a report released on Monday, November 25th. B. Riley analyst M. Mamtani now expects that the company will post earnings of ($1.12) per share for the year, down from their previous estimate of ($1.06). B. Riley currently has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for PDS Biotechnology’s current full-year earnings is ($1.18) per share. B. Riley also issued estimates for PDS Biotechnology’s Q4 2024 earnings at ($0.29) EPS, Q1 2025 earnings at ($0.34) EPS, Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.35) EPS, FY2025 earnings at ($1.37) EPS, FY2026 earnings at ($1.37) EPS, FY2027 earnings at ($1.52) EPS and FY2028 earnings at ($1.77) EPS.

Several other analysts also recently issued reports on PDSB. StockNews.com downgraded PDS Biotechnology from a “hold” rating to a “sell” rating in a research note on Saturday, November 9th. HC Wainwright restated a “buy” rating and set a $21.00 target price on shares of PDS Biotechnology in a research report on Friday, November 15th. Finally, Alliance Global Partners raised PDS Biotechnology to a “strong-buy” rating in a report on Wednesday, August 21st. One equities research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $11.67.

PDS Biotechnology Trading Down 2.8 %

Shares of NASDAQ:PDSB opened at $2.11 on Wednesday. PDS Biotechnology has a 12-month low of $1.53 and a 12-month high of $6.68. The business has a 50 day moving average of $3.08 and a 200-day moving average of $3.18. The company has a quick ratio of 2.84, a current ratio of 2.84 and a debt-to-equity ratio of 0.55. The stock has a market cap of $78.94 million, a PE ratio of -1.82 and a beta of 1.93.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Tempus Wealth Planning LLC acquired a new position in PDS Biotechnology during the 2nd quarter worth approximately $55,000. Ground Swell Capital LLC acquired a new stake in shares of PDS Biotechnology during the 2nd quarter valued at $67,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in PDS Biotechnology during the 2nd quarter worth $115,000. Vontobel Holding Ltd. increased its holdings in PDS Biotechnology by 233.3% in the 3rd quarter. Vontobel Holding Ltd. now owns 40,000 shares of the company’s stock worth $153,000 after purchasing an additional 28,000 shares in the last quarter. Finally, Squarepoint Ops LLC bought a new position in PDS Biotechnology in the second quarter valued at about $120,000. Institutional investors and hedge funds own 26.84% of the company’s stock.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.